Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stockUpcoming Result Date: Aug 04, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
3381.00 | 27,579 Cr | 71.41 | 16.68 | 0.07 | 21.54 | 28.77 | 19.52 | ||
1289.10 | 27,347 Cr | 78.38 | 11.01 | 0.00 | 14.05 | 18.23 | 9.62 | ||
1562.25 | 25,837 Cr | 104.71 | 20.05 | 0.10 | 19.14 | 22.56 | 10.60 | ||
192.05 | 25,569 Cr | -78.45 | 3.13 | 0.00 | -3.58 | 2.58 | -1.81 | ||
19020.25 | 24,345 Cr | 66.88 | 12.99 | 0.18 | 19.42 | 23.57 | 12.42 | ||
4708.70 | 21,456 Cr | 29.70 | 5.11 | 1.60 | 17.19 | 23.02 | 14.68 | ||
843.80 | 20,878 Cr | 31.52 | 4.42 | 0.21 | 11.70 | 13.63 | 8.58 | ||
| Median: 7 Co. | — | 1562.25 | 25,569 Cr | 66.88 | 11.01 | 0.10 | 17.19 | 22.56 | 10.60 |
Neuland Laboratories Ltd (NEULANDLAB) is currently trading at 18,859.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Neuland Laboratories is an Indian API manufacturer and CDMO that develops and commercializes small-molecule APIs, intermediates and peptide APIs, operating three cGMP manufacturing facilities (USFDA/EMA/PMDA audited), a 428-strong scientific R&D team and global commercial presence across 80+ countries with total reactor volume of 1,218,000 liters and ~2,131 employees. Q3FY26 results show total income of Rs.447.8 crore (+11.4% YoY) with EBITDA of Rs.85 crore at 19% margin (down 350bps YoY) and PAT of Rs.40.4 crore (-60% YoY); 9MFY26 capex was Rs.254 crore while net debt improved to a net cash position of Rs.(202.6) crore, reflecting heavy investment alongside deleveraging. The company is actively shifting mix from lower-margin Prime APIs toward higher-margin Specialty and CMS (CDMO) work: CMS accounted for 61% of Q3 revenue and 54% of 9M revenue, supported by 98 active CMS projects and an explicit peptide manufacturing push, positioning Neuland to capture the fast-growing peptide API market forecast to reach ~$14bn by 2030. Key operational risks and near-term drivers include product and customer concentration (CMS top-5 customers account for north of 90% of CMS revenue), working capital elevated at ~145 days driven by inventory and receivables, and quarter-to-quarter lumpiness from large individual CMS shipments and customer-side operational timing (for example paliperidone shipment delays).
Over the past 52 weeks, Neuland Laboratories Ltd has traded between a low of ₹11,500.00 and a high of ₹20,072.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Neuland Laboratories Ltd has a market capitalization of approximately 24,345.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Neuland Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 66.88 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 24,345.23 Cr, Neuland Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Neuland Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Neuland Laboratories Ltd is 66.88. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a ₹10,000 crore strategy aimed at making India a global biopharma manufacturing hub, focusing on biologics and biosimilars over the next five years.
Bearish
3
Neutral
7
Bullish
4
Bearish
6
Neutral
7
Bullish
33
Bearish
3
Neutral
0
Bullish
29
Neuland Laboratories is an Indian API manufacturer and CDMO that develops and commercializes small-molecule APIs, intermediates and peptide APIs, operating three cGMP manufacturing facilities (USFDA/EMA/PMDA audited), a 428-strong scientific R&D team and global commercial presence across 80+ countries with total reactor volume of 1,218,000 liters and ~2,131 employees.
Q3FY26 results show total income of Rs.447.8 crore (+11.4% YoY) with EBITDA of Rs.85 crore at 19% margin (down 350bps YoY) and PAT of Rs.40.4 crore (-60% YoY); 9MFY26 capex was Rs.254 crore while net debt improved to a net cash position of Rs.(202.6) crore, reflecting heavy investment alongside deleveraging.
The company is actively shifting mix from lower-margin Prime APIs toward higher-margin Specialty and CMS (CDMO) work: CMS accounted for 61% of Q3 revenue and 54% of 9M revenue, supported by 98 active CMS projects and an explicit peptide manufacturing push, positioning Neuland to capture the fast-growing peptide API market forecast to reach ~$14bn by 2030.
Key operational risks and near-term drivers include product and customer concentration (CMS top-5 customers account for north of 90% of CMS revenue), working capital elevated at ~145 days driven by inventory and receivables, and quarter-to-quarter lumpiness from large individual CMS shipments and customer-side operational timing (for example paliperidone shipment delays).
Pharmaceuticals & Biotechnology
Pharmaceuticals
24,345 Cr
Low Risk
66.9
37.2
2.6
13.0
20,072.00
11,500.00
Sales CAGR
Profit CAGR
ROE
ROCE
